Case Details
- Title: Martek Biosciences Corporation v Cargill International Trading Pte Ltd
- Citation: [2012] SGHC 35
- Court: High Court of the Republic of Singapore
- Date of Decision: 16 February 2012
- Case Number: Originating Summons No 1418 of 2009
- Tribunal/Court Below: Intellectual Property Office of Singapore (IPOS) — Deputy Registrar of Patents and Principal Assistant Registrar of Patents
- Coram: Tay Yong Kwang J
- Judgment Reserved: Yes
- Applicant/Plaintiff: Martek Biosciences Corporation
- Respondent/Defendant: Cargill International Trading Pte Ltd
- Counsel for Applicant: Dr Stanley Lai, SC and Vignesh Vaerhn (Allen & Gledhill LLP)
- Counsel for Respondent: Daniel Koh (instructed) (Eldan Law LLP) and Wendy Low Wei Ling (Rajah & Tann LLP)
- Legal Area(s): Patents and Inventions
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed) (“the Act”); Evidence Act (Cap 97, 1997 Rev Ed); Rules of Court (Cap 322, R5, 2006 Ed)
- Related Proceedings: Second appeal; first appeal concerned Singapore Patent P-No. 49307 in Martek Biosciences Corporation v Cargill International Trading [2011] 4 SLR 429 (“Martek v Cargill (No 1)”)
- Patent at Issue: Singapore Patent No. 42669 (“the Patent”), entitled “Arachidonic Acid and Methods for the Production and Use Thereof”
- Re-examination Trigger: IPOS Hearing Officers’ intention to cause re-examination under s 80(2) of the Act
- Re-examination Report: Dated 24 October 2008; made available on 6 November 2008
- Hearing Below: 9 to 12 February 2009
- Judicial Outcome (High Court): Applicant’s appeal allowed; Respondent’s appeal dismissed insofar as it related to certain aspects of the Decision
- Judgment Length: 17 pages, 9,976 words
- Cases Cited (as provided): [2012] SGHC 35
Summary
Martek Biosciences Corporation v Cargill International Trading Pte Ltd concerned the revocation of a Singapore patent relating to the production and use of arachidonic acid (“ARA”)—a long-chain omega-6 polyunsaturated fatty acid important for human nutrition, particularly in infant formula. The Respondent sought revocation of Martek’s Singapore Patent No. 42669 on two main grounds under the Patents Act: (i) that the claimed invention was not patentable, and (ii) that the patent was insufficient because the specifications did not disclose the invention clearly and completely enough for a person skilled in the art to perform it.
The High Court (Tay Yong Kwang J) reviewed the decision of the IPOS tribunal, which had found in favour of revocation. On appeal, the Court allowed Martek’s appeal and dismissed Cargill’s appeal in part. While the extract provided is truncated, the Court’s approach is evident from the reasoning structure: it scrutinised the tribunal’s handling of evidence (including expert testimony), assessed the patentability and sufficiency requirements under the Act, and corrected aspects of the tribunal’s conclusions.
What Were the Facts of This Case?
Martek Biosciences Corporation (“Martek”) is the proprietor of Singapore Patent No. 42669, granted by IPOS on 30 March 1999. The patent is entitled “Arachidonic Acid and Methods for the Production and Use Thereof”. The invention centres on processes for producing arachidonic acid-containing oils, preferably with low or no eicosapentaneoic acid (“EPA”), and on compositions and uses of such oils—particularly as additives for infant formula. The patent’s technical premise is that ARA cannot be synthesised de novo in humans and must therefore be supplied through diet, with infant formula being a key substitute for breast milk when mothers do not breastfeed or do not breastfeed for the entire period of rapid infant growth.
On 20 January 2006, Cargill International Trading Pte Ltd (“Cargill”) filed an application to revoke the Patent. The revocation application relied on two grounds under the Patents Act. First, Cargill argued that the invention was not a patentable invention under s 80(1)(a) of the Act. Second, Cargill argued that the patent was insufficient under s 80(1)(c), contending that the specifications did not disclose the invention clearly and completely for it to be performed by a person skilled in the art.
Martek responded by applying to amend the claims on 6 September 2006. These amendments were advertised in the Patents Journal on 30 October 2006, and no opposition was filed within the opposition window. The tribunal later held that the amendments were allowable because they did not introduce additional matter or extend the protection conferred by the patent. Importantly, the Respondent did not challenge the allowability of the amendments. Accordingly, the revocation proceedings proceeded on the basis of the amended claims.
At a case management conference on 28 April 2008, IPOS Hearing Officers indicated that they intended to cause the patent to be re-examined under s 80(2) of the Act. Cargill then filed a request for re-examination. The patent was re-examined by an examiner from the Australian Patent Office of IP Australia, who produced a re-examination report dated 24 October 2008 (made available to the parties on 6 November 2008). The tribunal hearing took place from 9 to 12 February 2009, and it was agreed that the Evidence Act and the Rules of Court would apply to the proceedings.
What Were the Key Legal Issues?
The High Court had to determine whether the tribunal was correct in revoking the patent. The legal issues were anchored in the Patents Act’s revocation framework. The first issue was whether the invention, as claimed (after the amendments), constituted a “patentable invention” within the meaning of s 80(1)(a). This typically engages questions of novelty and inventive step (and, depending on the pleaded particulars, whether the claimed subject matter falls within statutory exclusions or fails to meet the patentability threshold).
The second issue was sufficiency under s 80(1)(c). Sufficiency requires that the patent specifications disclose the invention clearly and completely so that a person skilled in the art can perform it. In biotechnology and chemical process patents, sufficiency disputes often turn on whether the specification provides adequate guidance on critical parameters, whether it enables the skilled person to reproduce the claimed results, and whether the disclosure is sufficiently enabling across the scope of the claims.
A further issue—procedural but legally significant—concerned the tribunal’s evaluation of evidence, particularly expert testimony. The extract shows that Martek challenged the tribunal’s approach to the Respondent’s expert evidence, including criticisms of an expert witness’s expertise, reliability, and ability to address technical matters such as fungal strains, culture conditions, and the distinction between lipid and fatty acid concepts. The High Court had to decide whether the tribunal’s evidential findings were sound and whether any errors affected the ultimate conclusions on patentability and sufficiency.
How Did the Court Analyse the Issues?
The Court’s analysis began with the appellate posture: this was the second appeal by Martek from decisions of IPOS tribunals. The Court noted that the parties were the same as in Martek v Cargill (No 1), where the High Court had already delivered judgment concerning another patent (Singapore Patent P-No. 49307). This context matters because it suggests that the parties’ technical and legal disputes were part of a broader pattern of litigation over related ARA patents, and the Court’s reasoning may have been informed by its earlier assessment of similar evidence and claim structures.
On evidence, the extract reveals a key feature of the Court’s approach: it did not treat the tribunal’s evidential handling as automatically decisive, but instead assessed whether the tribunal relied on the contested evidence and whether the evidence was necessary to the tribunal’s findings. Martek argued that the tribunal should have completely disregarded the Respondent’s expert, Dr Puah, on the basis that he lacked relevant expertise and that his evidence was unreliable or outside his competence. The tribunal, however, had taken a more cautious stance—declaring itself “inclined to share the general thrust” of Martek’s criticisms and finding that Dr Puah did not appear to possess relevant expertise, such that it could not draw much assistance from his evidence.
In response, Tay Yong Kwang J indicated that it was not necessary for the High Court to go as far as Martek requested (i.e., to disregard the evidence entirely). The Court reasoned that the tribunal did not rely on Dr Puah’s evidence in making its findings. The Respondent also confirmed at the hearing before the High Court that it was not relying on Dr Puah’s evidence and relied only on Dr Nga’s evidence and the objective text of the prior art. This reasoning reflects a disciplined appellate method: the Court focused on whether any alleged evidential deficiencies actually affected the tribunal’s reasoning and conclusions, rather than treating criticisms as sufficient in themselves.
Turning to the substantive patent issues, the Court would have assessed the amended claims against the revocation grounds. The patent’s essence, as summarised in the extract, is the production of triglyceride oils containing very high levels of ARA, with a target ARA:EPA ratio (with preferred thresholds such as at least 5:1, more preferably at least 10:1, and ideally around 20:1). The patent also contemplates cultivation conditions for Mortierella alpina (and other microbial sources) to achieve the desired fatty acid profile, followed by harvesting and extraction to produce an oil suitable for use as an additive for infant formula. The sufficiency analysis would therefore likely consider whether the specification provides enough detail about cultivation conditions, extraction, and selection of microbial strains to enable the skilled person to achieve the claimed ARA-rich triglyceride oils.
On patentability, the Court would have considered the prior art cited before the tribunal, labelled D1 to D10, with particular emphasis on D1, D4, D7 and D10. D1 concerned production of ARA by Mortierella alpina ATCC 3222 (published in 1991). D7 was International Patent WO 92/13086 titled “Arachidonic Acid and methods of the production and use thereof” (published in 1992). D4 related to an external preparation for skin (Japanese Patent No 64-38007, with an English translation). D10 concerned methods and pharmaceutical compositions for treating neurological disorders (WO 94/28913). The Court’s analysis would have addressed whether these disclosures anticipated the claimed subject matter or rendered it obvious, and whether the claimed selection of microbial species, process parameters, and ARA:EPA ratios were sufficiently distinct from the prior art.
Although the extract truncates the remainder of the judgment, the Court’s ultimate decision—allowing Martek’s appeal and dismissing Cargill’s appeal in part—indicates that at least one of the tribunal’s revocation findings was corrected. In practice, this often means that the High Court found either that the tribunal misapplied the legal test for patentability or sufficiency, or that the tribunal’s factual findings on the enabling nature of the disclosure or the novelty/inventive step assessment were not supported by the evidence and the prior art.
What Was the Outcome?
The High Court allowed Martek’s appeal against the IPOS tribunal’s decision that Cargill succeeded in revoking Martek’s Singapore Patent No. 42669. In other words, the revocation outcome reached below was not sustained in full on appeal.
The Court also dismissed Cargill’s appeal insofar as it related to certain aspects of the tribunal’s decision. The practical effect is that Martek retained the patent protection (at least to the extent not affected by the dismissed aspects), and Cargill’s attempt to remove the patent rights on the pleaded grounds failed at the appellate level.
Why Does This Case Matter?
This decision is significant for practitioners because it illustrates how Singapore courts approach appeals from IPOS patent revocation decisions, particularly where the dispute involves both substantive patent law (patentability and sufficiency) and the reliability of expert evidence. The Court’s treatment of Dr Puah’s testimony underscores an important evidential principle: appellate courts will focus on whether the tribunal actually relied on the contested evidence and whether any alleged deficiencies were causally linked to the tribunal’s conclusions.
From a patent drafting and prosecution perspective, the case also highlights the centrality of sufficiency in process and biotechnology patents. Where claims are framed around achieving specific compositional outcomes—such as high ARA levels and particular ARA:EPA ratios—the sufficiency inquiry will likely examine whether the specification provides adequate enabling instructions across the claim scope. This is especially relevant where the patent involves cultivation conditions, microbial strains, and extraction steps that may be sensitive to parameter variations.
Finally, the case matters because it sits within a broader litigation landscape between the same parties over related ARA patents. For law students and litigators, it demonstrates how courts may build coherence across multiple patent disputes by referencing earlier judgments and by evaluating evidence and prior art in a structured manner. Practitioners should therefore treat this decision as part of a developing body of Singapore jurisprudence on revocation, sufficiency, and the evidential standards applied in patent validity challenges.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including:
- Section 80(1)(a) (patentability ground for revocation)
- Section 80(1)(c) (insufficiency ground for revocation)
- Section 80(2) (re-examination mechanism)
- Evidence Act (Cap 97, 1997 Rev Ed)
- Rules of Court (Cap 322, R5, 2006 Ed)
Cases Cited
- Martek Biosciences Corporation v Cargill International Trading [2011] 4 SLR 429 (“Martek v Cargill (No 1)”)
- [2012] SGHC 35 (this case)
Source Documents
This article analyses [2012] SGHC 35 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.